Remdesivir for Treating Non-Hospitalized Patients with COVID-19 | Zendy

Zahoor Ahmed Shah | Zendy; Abdul Shakoor | Zendy; Hammad-Ur- Rehman Bhatti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Remdesivir for Treating Non-Hospitalized Patients with COVID-19

Author(s) -

Zahoor Ahmed Shah,

Abdul Shakoor,

Hammad-Ur- Rehman Bhatti

Publication year - 2022

Publication title -

pakistan journal of medical and health sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.114

H-Index - 7

ISSN - 1996-7195

DOI - 10.53350/pjmhs22162156

Subject(s) - medicine , viral load , covid-19 , comorbidity , retrospective cohort study , diabetes mellitus , group b , disease , immunology , virus , virology , infectious disease (medical specialty) , endocrinology , outbreak

Aim: To examine the effect of remdesivir for treating non-hospitalized patients with COVID-19. Study design: Retrospective study Place and duration of study: Department of Medicine, Bolan Medical College, Quetta from 1st April 2021 to 30th September 2021. Methodology: One hundred patients were enrolled and divided into group A and group B within the age of 24-70 years. Group A was receiving remdesivir while group B is not receiving remdesivir. The clinical variables, BMI, comorbidities, duration of disease severity and viral load were determined. RT-PCR was conducted to determine viral load. Results: The mean age of study participants was 50±15 years with greater number of males. Diabetes was the major comorbidity. The time duration was decreased in group A upto 5 days and 8 days in group B. The viral load was decreased by mean value 6.32±1.76 to 6.2±1.78 in group B then group A respectively. Conclusion: Remdesivir is effective in COVID-19 treatment. Keywords: Remdesivir, COVID-19, Viral load

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research